BioStable Science & Engineering Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $6M
Latest Deal Amount
  • Investors
  • 8

BioStable Science & Engineering General Information

Description

Developer of cardiovascular valve repair technologies designed to provide an alternative to valve replacement for patients with aortic valve disease. The company's technologies are designed to simplify and standardize aortic valve repair, include annuloplasty devices, instrumentation, and repeatable implantation procedures, enabling surgeons to offer the recognized clinical benefits of valve repair to patients undergoing surgical correction of aortic insufficiency or aortic root aneurysm.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Surgical Devices
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 2621 Ridgepoint Drive
  • Suite 100
  • Austin, TX 78754
  • United States
+1 (512) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioStable Science & Engineering Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 21-Feb-2020 $6M 000.00 0000 Completed Generating Revenue
3. Later Stage VC (Series B) 29-Apr-2015 00.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series B) 28-Dec-2012 $6.5M $12M 000.00 Completed Startup
1. Early Stage VC (Series A) 22-Aug-2008 $5.5M $5.5M 000 Completed Startup
To view BioStable Science & Engineering’s complete valuation and funding history, request access »

BioStable Science & Engineering Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 000
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 3,374,792 $0.001000 $0.16 $2 $2 1x $2 21.42%
To view BioStable Science & Engineering’s complete cap table history, request access »

BioStable Science & Engineering Executive Team (12)

Name Title Board Seat Contact Info
John Wheeler Chief Executive Officer, President & Board Member
Gae Busch-Petersen Controller
Al Beavan Vice President of Engineering & Co-Founder
Julie Thomas Vice President, Operations
Rusty Phillips Ph.D Vice President, Technology
You’re viewing 5 of 12 executive team members. Get the full list »

BioStable Science & Engineering Board Members (7)

Name Representing Role Since
David Strong Orlando Health Board Member 000 0000
James Eadie MD Santé Board Observer 000 0000
Joe Cunningham MD Santé Board Member 000 0000
John Wheeler BioStable Science & Engineering Chief Executive Officer, President & Board Member 000 0000
Joseph Lovett Louisiana Funds Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

BioStable Science & Engineering Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioStable Science & Engineering Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Longmeadow Capital Partners PE/Buyout Minority 000 0000 000000 0
Louisiana Funds Venture Capital Minority 000 0000 000000 0
Orlando Health Corporation Minority 000 0000 000000 0
Rex Health Ventures Corporate Venture Capital Minority 000 0000 000000 0
Santen Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »